Market Cap: $28.37M
NI
NurExone Biologic Inc.
NRX.V
TSXV (Toronto Stock Exchange Ventures)CAD
Market Cap: $28.37M
Successful parallel production process maintains consistency while doubling exosome yield without increasing manufacturing time TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Bi…
NurExone Biologic is moving its exosome platform into a more demanding phase: proving that a preclinical therapy can be manufactured consistently enough to support human testing and, eventually, comme…
October 09, 2026 16:03 ET | Source: NurExone Biologic Inc TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “…
Based on an article by Vincent Uhr of Dr. Eva Reuter Investor Relations reviewed by Samuel Boltruczyk Regenerative medicine has long since moved beyond the search for a single miracle therapy. The mar…
CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE…
Two tracks, two opportunities The standard preclinical biotech is built around a single therapeutic program. All value creation depends on that one drug candidate reaching human trials, then regulator…
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- N…
The quarter, in plain language Reporting quarters at preclinical-stage biotechs matter less for the current-period P&L and more for what the operational activity around them signals about the pace of…
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-…
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exo…
Most preclinical biotech companies are single-indication, cash-burning bets. One drug, one indication, one binary FDA outcome years in the future, and steady dilution in the meantime. NurExone Biologi…
- On August 12, 2026, NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) announced that its U.S. subsidiary Exo-Top Inc. had signed a binding memorandum of understanding with Made Scientific,…
Roughly 900,000 people around the world sustain a new acute spinal cord injury every year. About 18,000 of them are in the United States. The lifetime direct-care cost for a single patient often excee…
Nanotechnology is transforming industry and medicine – and NurExone Biologic Inc. is positioning itself at the heart of this future market with its exosome-based platform. With progress in reproducibl…